- THRIVE-2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites - - THRIVE topline readout in patients with active TED on track for ...
Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results